1. Low-dose apatinib combined with neoadjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer (LANCET): a single-center, single-arm, phase II trial
   Ciqiu Yang et al, 2022, Therapeutic Advances in Medical Oncology CrossRef
2. Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key
   Connie Rabanal et al, 2017, World Journal of Clinical Oncology CrossRef
3. Clinical overview of metronomic chemotherapy in breast cancer
   Elisabetta Munzone et al, 2015, Nature Reviews Clinical Oncology CrossRef
4. Metronomic maintenance chemotherapy in patients presenting with paraneoplastic autoimmune hepatitis with recurrent thymic carcinoma
   Derya Kivrak Salim et al, 2016, Journal of Oncology Pharmacy Practice CrossRef
5. Real-World Data on Apatinib Efficacy - Results of a Retrospective Study in Metastatic Breast Cancer Patients Pretreated With Multiline Treatment
   Zhaoyun Liu et al, 2021, Frontiers in Oncology CrossRef
6. Indication of metronomic chemotherapy for metastatic breast cancer: Clinical outcomes and responsive subtypes
   KEIICHI KONTANI et al, 2016, Molecular and Clinical Oncology CrossRef